

## **BrainStorm Cell Therapeutics and Octane Biotech Announce Advancement of Novel Bioreactor for Commercial-Scale Production of NurOwn® Stem Cells**

**Hackensack, NJ & Petach Tikvah, Israel – November 11, 2015** – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have made significant progress toward the development of a novel bioreactor for industrial-scale manufacture of BrainStorm’s NurOwn® neurotrophic-factor secreting mesenchymal stem cells.

The proprietary bioreactor will utilize Octane’s existing Cocoon™ cell therapy system coupled with a customized disposable cartridge, specifically designed for BrainStorm’s NurOwn stem cell therapy. The novel Cocoon system integrates upstream and downstream processing including cell source isolation and cell expansion, cell collection, cell washing and final product formation, in a closed, single-use disposable cassette. By integrating multiple steps, this highly innovative technology, unlike other bioreactor systems, is expected to permit substantial upscaling of cell manufacturing capabilities, allowing the production of more cells in less time.

Recently, researchers from BrainStorm and Octane have made important progress in the automation of complexities associated with the process. As a result, the teams have further refined development of the cassette and are nearer to introducing a fully automated bioreactor for BrainStorm’s NurOwn stem cells.

“The ability to successfully manufacture our NurOwn cells at commercial scale volumes is another important milestone for BrainStorm,” commented Chaim Lebovits, CEO of BrainStorm. “The progress we have made, by leveraging Octane’s Cocoon system, moves us one step closer to our ultimately goal of providing patients and physicians with an improved standard of care for treating neurodegenerative diseases.”

Dr. Timothy Smith, CEO of Octane Biotech further commented, “The Octane Cocoon platform was designed to facilitate cell manufacturing and the creation of a novel cassette to incorporate BrainStorm’s proprietary NurOwn technology is a perfect complement. We are pleased to be working with BrainStorm, and look forward to helping advance their important work.”

### ***About BrainStorm Cell Therapeutics Inc.***

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United

States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial at three major clinical centers in the United States. For more information, visit the company's website at [www.brainstorm-cell.com](http://www.brainstorm-cell.com).

### ***About Octane Biotech***

Octane develops innovative bioreactor-based systems to meet the production challenges inherent in the progressive scale-up of manual cell culture protocols. The company's unique Automated Cell & Tissue Engineering System (ACTES) solution integrates state-of-the-art bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech Inc. is one of three affiliated companies within the Octane Medical Group. For more information, visit the company's website at [www.octaneco.com](http://www.octaneco.com).

### ***Safe Harbor Statement***

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

### **CONTACTS**

Media:

Uri Yablonka

Chief Operating Officer

BRAINSTORM CELL THERAPEUTICS INC.

201-488-0460

[uri@brainstorm-cell.com](mailto:uri@brainstorm-cell.com)

Investors:

Michael Rice

LIFESCI ADVISORS, LLC

Phone: (646) 597-6979

[mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)

# # #